Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|September 24, 2018
DSM to Highlight Vitamin and Lipid Portfolio at CPhI Worldwide 2018
Author(s)Pharmaceutical Technology Editors
The company will showcase the evolving role of vitamins and lipid APIs in pharmaceutical applications at CPhI Worldwide 2018.
Advertisement
DSM, a supplier of vitamins, carotenoids, and lipid APIs, will exhibit its portfolio of vitamins and lipid APIs at CPhI Worldwide, taking place in Madrid, Spain on Oct. 9–11, 2018.
The company’s pipeline is focused on addressing the latest research on the therapeutic effects of vitamins, as well as the development of vitamin combinations with established APIs. While combinations such as nonsteroidal anti-inflammatory drugs with B vitamins and contraceptives with folate are commercially available in several countries, DSM brings vitamin combinations to market for indications such as chronic low back pain, osteoarthritis, hypertension, type 2 diabetes, inflammatory bowel disease, and ulcer treatment.
DSM can provide access to both United States drug master files and certificates of suitability for all 13 of its vitamins, providing its pharmaceutical partners an advantage by accelerating the registration and market entry process, which enables timelier patient access, the company reports.
The company’s expertise in chemical synthesis and biotechnology helps to ensure products meet sustainability standards. Learn more at Stand 7B10 at 4pm–6pm on Oct. 9 and 10 at CPhI Worldwide 2018.
Source:
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement